智通财经APP讯，白云山(00874)发布截至2025年12月31日止年度业绩，该集团取得营业收入776.56亿元，同比增加3.55%;归属于本公司股东的净利润29.83亿元，同比增加5.21%;基本每股收益1.835元，拟派发每股现金红利0.45元。
2025年，本集团紧紧围绕生物医药健康的战略定位，依托产业优势，充分挖掘自身资源与资产，全面推进生产经营各项工作，推动业务持续稳定增长。
进一步推动中药材种植基地规范化、标准化建设，不断增强对关键中药原料生产与供应的掌控能力;巩固特色原料药的发展优势，不断丰富特色原料药产品线，同时加大对新品原料药的拓展布局力度，稳步拓展国内外市场。
持续加强与头部连锁及电商的深度合作，进一步做强优势品种、挖潜沉睡品种、培育重磅新品，同时紧抓质量安全、不断提升产品品质，增强市场核心竞争力，推动医药业务稳定发展。本报告期内，消渴丸、保济系列、阿莫西林系列、安宫牛黄丸、舒筋健腰丸、消炎镇痛膏、甲基橙皮甘、坎地沙坦酯片等产品的销售收入实现同比较快增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.